Neutropenia occurs when patients have a low level of neutrophils which is a type of white blood cells.
This report contains market size and forecasts of Neutropenia Biologic Drug Treatment in global, including the following market information:
Global Neutropenia Biologic Drug Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Neutropenia Biologic Drug Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Neutropenia Biologic Drug Treatment companies in 2021 (%)
The global Neutropenia Biologic Drug Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Filgrastim Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neutropenia Biologic Drug Treatment include Amgen, Novartis, Pfizer, Baxter International, Cellerant Therapeutics, Dong-A ST Co.,Ltd., Myelo Therapeutics GmbH, Sanofi and Teva Pharmaceutical Industries Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neutropenia Biologic Drug Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neutropenia Biologic Drug Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neutropenia Biologic Drug Treatment Market Segment Percentages, by Type, 2021 (%)
Filgrastim
Pegfilgrastim
Lenograstim
Lipegfilgrastim
Sargramostim
Global Neutropenia Biologic Drug Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neutropenia Biologic Drug Treatment Market Segment Percentages, by Application, 2021 (%)
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Global Neutropenia Biologic Drug Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neutropenia Biologic Drug Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neutropenia Biologic Drug Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Neutropenia Biologic Drug Treatment revenues share in global market, 2021 (%)
Key companies Neutropenia Biologic Drug Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Neutropenia Biologic Drug Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Novartis
Pfizer
Baxter International
Cellerant Therapeutics
Dong-A ST Co.,Ltd.
Myelo Therapeutics GmbH
Sanofi
Teva Pharmaceutical Industries Ltd.
Kyowa Kirin
CVS Health
Partner Therapeutics
Enzychem Lifesciences Corporation